Currently, five PARP inhibitor drugs are running in clinical trials for approval. All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with ...

Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More Ovarian cancer is the malignancy with the highest rate of death from tumors of the female ...

In early June, clinical results with BiPar's experimental drug BSI-201 and AstraZeneca's small-molecule PARP inhibitor olaparib were presented at the American Society of Clinical Oncology meeting ...

Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers. Now the UK pharma is aiming to build ...

One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer. The alliance is important for Tesaro, which is ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities. Recruitment will commence at leading U.S. trial sites, with the potential ...

Research from our laboratory and others showed that combining the PARP inhibitor with a demethylation inhibitor can enhance DNA damage and cytotoxicity to tumors. We developed a new polymer that is ...

To Know in detail about the PARP Inhibitors market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: PARP Inhibitors Market Forecast Report Some of the key insights of ...

Know about the revolutionary therapies, personalised medicine and cancer treatments that are changing the game!